ClinicalTrials.gov
public full text
Public Domain
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine#1072514
- Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence#897439
- Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy#995502
- Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056#969790
- Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults#839194
Record · ID 1114876
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive